Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
$0.01
-1.1%
$0.01
$0.00
$0.04
N/AN/A100,005 shs85,513 shs
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
$0.00
-40.0%
$0.00
$0.00
$0.11
N/AN/A1.37 million shs570,300 shs
LBPSW
4D pharma
$0.00
$0.04
$1.29
N/AN/A20,931 shsN/A
Parnell Pharmaceuticals Holdings Ltd stock logo
PARNF
Parnell Pharmaceuticals
$0.08
$0.08
$0.05
$0.35
N/A26.33N/AN/A
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
-1.14%+2.35%+17.57%+6.10%-5.43%
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
-40.00%-25.00%-85.00%-98.21%-99.67%
LBPSW
4D pharma
0.00%0.00%0.00%0.00%0.00%
Parnell Pharmaceuticals Holdings Ltd stock logo
PARNF
Parnell Pharmaceuticals
0.00%0.00%0.00%0.00%+79,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
N/AN/AN/AN/AN/AN/AN/AN/A
LBPSW
4D pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Parnell Pharmaceuticals Holdings Ltd stock logo
PARNF
Parnell Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
0.00
N/AN/AN/A
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
0.00
N/AN/AN/A
LBPSW
4D pharma
0.00
N/AN/AN/A
Parnell Pharmaceuticals Holdings Ltd stock logo
PARNF
Parnell Pharmaceuticals
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/AN/A
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
N/AN/AN/AN/AN/AN/A
LBPSW
4D pharma
$522KN/AN/AN/AN/AN/A
Parnell Pharmaceuticals Holdings Ltd stock logo
PARNF
Parnell Pharmaceuticals
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/A0.00N/AN/AN/AN/AN/A
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
N/AN/A0.00N/AN/AN/AN/AN/A
LBPSW
4D pharma
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Parnell Pharmaceuticals Holdings Ltd stock logo
PARNF
Parnell Pharmaceuticals
N/AN/A0.00N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/A
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
N/AN/AN/AN/AN/A
LBPSW
4D pharma
N/AN/AN/AN/AN/A
Parnell Pharmaceuticals Holdings Ltd stock logo
PARNF
Parnell Pharmaceuticals
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/A
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
N/A
LBPSW
4D pharma
N/A
Parnell Pharmaceuticals Holdings Ltd stock logo
PARNF
Parnell Pharmaceuticals
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
7N/AN/ANot Optionable
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
460N/AN/ANot Optionable
LBPSW
4D pharma
N/AN/AN/ANot Optionable
Parnell Pharmaceuticals Holdings Ltd stock logo
PARNF
Parnell Pharmaceuticals
51N/AN/ANot Optionable

Recent News About These Companies

Parnell Pharmaceuticals Holdings Ltd.
The Birth Parent Experience
Parnell Pharmaceuticals Holdings Ltd (PARNF)
The best Netflix original movies right now
How Parents Harm Their Children

Media Sentiment Over Time

180 Life Sciences stock logo

180 Life Sciences NASDAQ:ATNFW

$0.0087 0.00 (-1.14%)
As of 06/20/2025 03:42 PM Eastern

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

4Front Ventures stock logo

4Front Ventures OTCMKTS:FFNTF

$0.0003 0.00 (-40.00%)
As of 06/20/2025 03:56 PM Eastern

4Front Ventures Corp. owns and manages licensed cannabis facilities in state-licensed markets in the United States. The company operates through THC Cannabis and CBD Wellness segments. THC Cannabis segment engages in the cultivation, production, manufacturing, and distribution of THC cannabis products to owned dispensaries and third party retailers; and provision of ancillary services. This segment sells equipment, supplies, and intellectual property to cannabis producers; and leases real estate properties. The CBD Wellness segment sells non-THC hemp derived products. In addition, it operates dispensaries in the Massachusetts, Illinois, and Michigan primarily under the MISSION brand name. 4Front Ventures Corp. was founded in 2011 and is based in Phoenix, Arizona.

4D pharma NASDAQ:LBPSW

4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. The company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumors. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.

Parnell Pharmaceuticals stock logo

Parnell Pharmaceuticals OTCMKTS:PARNF

$0.08 0.00 (0.00%)
As of 04/22/2025

Parnell Pharmaceuticals Holdings Ltd, a commercial-stage pharmaceutical company, focuses on developing, manufacturing, and marketing animal pharmaceutical products worldwide. The company operates through four segments: Companion Animal, Production Animal - U.S., Production Animal - Rest of World, and Manufacturing Operations. It markets various products, including estroPLAN and GONAbreed reproductive hormone products for enhancing cattle breeding performance; Zydax for the treatment of osteoarthritis (OA) in dogs and horses; and Glyde, a nutraceutical product for the treatment of OA, as well as Parnell PROcept, which adds an additional injection of estroPLAN after the first injection. The company also offers mySYNCH, a digital tool to help veterinarians and producers optimize reproduction and maximize economic gains. Parnell Pharmaceuticals Holdings Ltd was incorporated in 2009 and is headquartered in Alexandria, Australia.